TCMD
Neutral signalScored 2026-08-13 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Tactile Systems Technology, Inc.
- Nom
- Tactile Systems Technology, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $536.9M
- Employés
- 1,086
- PDG
- Sheri Louise Dodd
- Site web
- https://www.tactilemedical.com
- Marché
- ELMD
Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 10 978 titres (~323 242,82 $ US)
- Insiders
- Dodd Sheri Louise
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$323,243
Avg sell (VWAP, 90d window) $29.44 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-10
- Last synced
-
2026-08-16 09:56:14
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-10 | Dodd Sheri Louise | Sell · S | 10,978 | $29.44 | $323,243 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2019-01-23 | Donna Shalala | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-08-13 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
TCMD exhibits a genuinely strong financial foundation — high liquidity (90), improving fundamentals (85), and a credible deleveraging trajectory — which anchors the investment thesis.
The first sentence of the analysis written for TCMD on 2026-08-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 4.03 · operating margin 8.9%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 75.2% | 74.0% | 71.1% | 71.3% | 71.2% | |
| Ebit Margin | 9.8% | 8.7% | 7.3% | -5.1% | -1.1% | |
| Ebitda Margin | 11.8% | 11.0% | 9.6% | 0.7% | 0.7% | |
| Operating Profit Margin | 8.9% | 7.6% | 6.6% | -5.2% | -0.8% | |
| Pretax Profit Margin | 9.5% | 8.0% | 5.7% | -6.3% | -1.1% | |
| Continuous Operations Profit Margin | 5.8% | 5.8% | 10.4% | -7.2% | -5.7% | |
| Net Profit Margin | 5.8% | 5.8% | 10.4% | -7.2% | -5.7% | |
| Bottom Line Profit Margin | 5.8% | 5.8% | 10.4% | -7.2% | -5.7% | |
| Current Ratio | 4.033 | 4.362 | 3.539 | 1.862 | 3.295 | |
| Quick Ratio | 3.690 | 3.904 | 2.990 | 1.502 | 2.737 | |
| Solvency Ratio | 0.467 | 0.292 | 0.399 | -0.026 | -0.070 | |
| Cash Ratio | 2.037 | 2.318 | 1.487 | 0.341 | 0.819 | |
| Price To Earnings Ratio | 34.940 | 24.127 | 11.532 | -12.899 | -31.717 | |
| Price To Earnings Growth Ratio | 2.067 | -0.564 | -0.048 | -0.267 | -0.017 | |
| Forward Price To Earnings Growth Ratio | 2.067 | -0.564 | -0.048 | -0.267 | -0.017 | |
| Price To Earnings Diluted Ratio | 35.366 | 24.471 | 11.626 | -12.899 | -31.717 | |
| Price To Earnings Diluted Growth Ratio | 2.063 | -0.568 | -0.049 | -0.267 | -0.017 | |
| Price To Book Ratio | 3.030 | 1.889 | 1.693 | 1.898 | 2.927 | |
| Price To Sales Ratio | 2.013 | 1.396 | 1.195 | 0.934 | 1.804 | |
| Price To Free Cash Flow Ratio | 16.406 | 10.725 | 9.823 | 70.046 | 1,359.644 | |
| Price To Operating Cash Flow Ratio | 15.494 | 10.063 | 9.143 | 44.227 | 142.631 | |
| Debt To Assets Ratio | 0.058 | 0.151 | 0.179 | 0.283 | 0.330 | |
| Debt To Equity Ratio | 0.073 | 0.208 | 0.260 | 0.595 | 0.629 | |
| Debt To Capital Ratio | 0.068 | 0.172 | 0.206 | 0.373 | 0.386 | |
| Long Term Debt To Capital Ratio | 0.055 | 0.097 | 0.119 | 0.274 | 0.288 | |
| Financial Leverage Ratio | 1.251 | 1.375 | 1.453 | 2.100 | 1.905 | |
| Working Capital Turnover Ratio | 2.524 | 2.430 | 3.437 | 3.669 | 2.364 | |
| Operating Cash Flow Ratio | 1.045 | 0.999 | 0.873 | 0.081 | 0.076 | |
| Operating Cash Flow Sales Ratio | 0.130 | 0.139 | 0.131 | 0.021 | 0.013 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.944 | 0.938 | 0.931 | 0.631 | 0.105 | |
| Debt Service Coverage Ratio | 25.787 | 5.127 | 5.513 | -0.112 | -2.747 | |
| Interest Coverage Ratio | 28.207 | 10.638 | 4.350 | -4.576 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 13.753 | 12.130 | 1.755 | 0.889 | |
| Operating Cash Flow Coverage Ratio | 2.683 | 0.901 | 0.712 | 0.072 | 0.033 | |
| Capital Expenditure Coverage Ratio | 17.988 | 16.204 | 14.452 | 2.713 | 1.117 | |
| Dividend Paid And Capex Coverage Ratio | 17.988 | 16.204 | 14.452 | 2.713 | 1.117 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 15.270 | 11.116 | 12.007 | 160.664 | 308.100 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 75.2% | ▲1.2% | ▲2.6% |
| Ebit Margin | 9.8% | ▲1.1% | ▲5.9% |
| Ebitda Margin | 11.8% | ▲0.8% | ▲5.1% |
| Operating Profit Margin | 8.9% | ▲1.3% | ▲5.5% |
| Pretax Profit Margin | 9.5% | ▲1.5% | ▲6.3% |
| Continuous Operations Profit Margin | 5.8% | 0.0% | ▲4.0% |
| Net Profit Margin | 5.8% | 0.0% | ▲4.0% |
| Bottom Line Profit Margin | 5.8% | 0.0% | ▲4.0% |
| Current Ratio | 4.033 | ▼-0.330 | ▲0.615 |
| Quick Ratio | 3.690 | ▼-0.213 | ▲0.726 |
| Solvency Ratio | 0.468 | ▲0.175 | ▲0.255 |
| Cash Ratio | 2.037 | ▼-0.281 | ▲0.637 |
| Price To Earnings Ratio | 34.940 | ▲10.813 | ▲29.743 |
| Price To Earnings Growth Ratio | 2.067 | ▲2.632 | ▲1.833 |
| Forward Price To Earnings Growth Ratio | 2.067 | ▲2.632 | ▲1.833 |
| Price To Earnings Diluted Ratio | 35.366 | ▲10.894 | ▲29.996 |
| Price To Earnings Diluted Growth Ratio | 2.063 | ▲2.631 | ▲1.831 |
| Price To Book Ratio | 3.030 | ▲1.141 | ▲0.743 |
| Price To Sales Ratio | 2.013 | ▲0.617 | ▲0.545 |
| Price To Free Cash Flow Ratio | 16.406 | ▲5.681 | ▼-276.923 |
| Price To Operating Cash Flow Ratio | 15.494 | ▲5.431 | ▼-28.818 |
| Debt To Assets Ratio | 0.058 | ▼-0.093 | ▼-0.142 |
| Debt To Equity Ratio | 0.073 | ▼-0.135 | ▼-0.280 |
| Debt To Capital Ratio | 0.068 | ▼-0.104 | ▼-0.173 |
| Long Term Debt To Capital Ratio | 0.055 | ▼-0.042 | ▼-0.112 |
| Financial Leverage Ratio | 1.251 | ▼-0.124 | ▼-0.366 |
| Working Capital Turnover Ratio | 2.524 | ▲0.094 | ▼-0.361 |
| Operating Cash Flow Ratio | 1.045 | ▲0.046 | ▲0.430 |
| Operating Cash Flow Sales Ratio | 0.130 | ▼-0.009 | ▲0.043 |
| Free Cash Flow Operating Cash Flow Ratio | 0.944 | ▲0.006 | ▲0.234 |
| Debt Service Coverage Ratio | 25.787 | ▲20.660 | ▲19.073 |
| Interest Coverage Ratio | 28.207 | ▲17.569 | ▲20.483 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-13.753 | ▼-5.705 |
| Operating Cash Flow Coverage Ratio | 2.683 | ▲1.782 | ▲1.803 |
| Capital Expenditure Coverage Ratio | 17.988 | ▲1.784 | ▲7.493 |
| Dividend Paid And Capex Coverage Ratio | 17.988 | ▲1.784 | ▲7.493 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 15.270 | ▲4.154 | ▼-86.162 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $663.3M | $409.1M | $327.8M | $230.4M | $375.3M | |
| Enterprise value | $595.8M | $359.9M | $317.2M | $280.7M | $427.6M | |
| EV / Sales | 1.81x | 1.23x | 1.16x | 1.14x | 2.06x | |
| EV / Op. cash flow | 13.92x | 8.85x | 8.85x | 53.88x | 162.54x | |
| EV / Free cash flow | 14.74x | 9.43x | 9.50x | 85.34x | 1549.43x | |
| EV / EBITDA | 15.27x | 11.12x | 12.01x | 160.66x | 308.10x | |
| Net debt / EBITDA | -1.73x | -1.52x | -0.40x | 28.79x | 37.74x | |
| Current ratio | 4.03x | 4.36x | 3.54x | 1.86x | 3.29x | |
| Income quality | 2.24x | 2.40x | 1.26x | -0.29x | -0.22x | |
| Graham number | $13 | $12 | $15 | — | — | |
| Graham net-net | $3 | $3 | $1 | -$2 | -$1 | |
| Tax burden | 60.9% | 72.2% | 180.8% | 115.5% | 515.1% | |
| Interest burden | 96.8% | 91.8% | 79.2% | 122.0% | 100.0% | |
| Working capital | $124.2M | $136.9M | $104.2M | $55.4M | $79.1M | |
| Invested capital | $213.4M | $232.9M | $207.3M | $164.3M | $195.0M | |
| Return on assets | 7.0% | 5.7% | 10.1% | -7.0% | -4.8% | |
| Operating ROA | 10.2% | 7.7% | 6.7% | -5.1% | -0.8% | |
| Return on tangible assets | 9.4% | 7.6% | 14.0% | -10.3% | -7.4% | |
| Return on equity | 8.7% | 7.8% | 14.7% | -14.7% | -9.2% | |
| Return on invested capital | 7.5% | 6.1% | 7.3% | -6.5% | -0.8% | |
| Return on capital employed | 12.6% | 8.6% | 7.5% | -6.7% | -0.8% | |
| Earnings yield | 2.9% | 4.1% | 8.7% | -7.8% | -3.1% | |
| Free cash flow yield | 6.1% | 9.3% | 10.2% | 1.4% | 0.1% | |
| Capex / Op. cash flow | 5.6% | 6.2% | 6.9% | 36.9% | 89.5% | |
| Capex / Depreciation | 35.8% | 36.9% | 38.2% | 30.6% | 63.6% | |
| Capex / Sales | 0.7% | 0.9% | 0.9% | 0.8% | 1.1% | |
| SG&A / Sales | 63.7% | 62.5% | 61.7% | 67.8% | 69.0% | |
| R&D / Sales | 2.6% | 3.0% | 2.9% | 2.9% | 2.7% | |
| Stock comp / Sales | 2.5% | 2.7% | 2.8% | 3.9% | 4.9% | |
| Intangibles / Total assets | 25.6% | 24.8% | 27.6% | 31.9% | 34.9% | |
| Days sales outstanding | 49d | 56d | 57d | 81d | 87d | |
| Days payables outstanding | 22d | 27d | 31d | 51d | 31d | |
| Operating cycle | 111d | 145d | 161d | 200d | 204d | |
| Cash conversion cycle | 89d | 118d | 130d | 149d | 173d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-10 Tactile Systems Technology, Inc. (TCMD) Q2 2026 Earnings Call Transcript Tactile Systems Technology, Inc. (TCMD) Q2 2026 Earnings Call Transcript
- 2026-08-10 Tactile Systems Technology Q2 Earnings Call Highlights Tactile Systems Technology NASDAQ: TCMD, doing business as Tactile Medical, reported second-quarter revenue growth and higher profitability, led by its lymphedema business, while updating its full-year outlook to reflect temporary inventory effects in its airway-clearance segment.
- 2026-08-10 Tactile Systems Technology (TCMD) Beats Q2 Earnings and Revenue Estimates Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.14 per share a year ago.
- 2026-07-21 Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026 MINNEAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2026 financial results will be released after the market closes on Monday, August 10, 2026.
- 2026-07-13 Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression Discreet, Battery-Powered Device Reaches Patients at Earlier Stages of Disease Progression
- 2026-06-29 Tactile Systems Technology (TCMD) Moves 8.1% Higher: Will This Strength Last? Tactile Systems Technology (TCMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-06-02 Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system. The next-generation system maintains its indication for use as a treatment option for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis, across pediatric and geriatric populations, while introducing enhancements to patient comfort, ease of use, and connected care capabilities to support long-term therapy adherence.
- 2026-05-20 Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the William Blair 46th Annual Growth Stock Conference, which is being held at the Loews Hotel in Chicago, IL, from June 2-4, 2026. Management will present on Tuesday, June 2, at 9:20 a.m. Central Time.